Analyst Reports, page-3

I thought BioShares report was fair although they also no longer have a vested interest and on a spec B rating these days so maybe why not as pumped as they have been previously. I can see where they maybe chose not to touch Genetech's extension as "screaming" validation though - company & shareholders were really hoping for them to license it there but again they chose to just extend it and keep looking. It's happened before with previous deals as well (Roche/ Genentech & Janssen) where they have extended them and then eventually handed back (hopefully not the case this time). Nearly 4x the cash of the research grant is indeed bumper but not sure it's "screaming validation" ?

NGPT has always been a pretty good annual conference for the company to attend each year - coming up again next week with another presentation on FPP's and delivery same theme as the last few from memory.